0314 (0314) Fair Value & Analysis

Healthcare · Market cap HK$977M

0 0314 0314 · HK

PriceHK$1.34

Fair ValueHK$0.3900

Upside-70.9%

Quality46/100

Evidence: Low Range HK$0.3900 – HK$0.3900

Fair value as of: Jul 1, 2026

From 6 valuation models · updated today

Share price −7.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.18 – HK$6.69 · the HK$1.34 price screens above the HK$0.3900 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0314 (0314) currently trades at HK$1.34, while our model-based Fair Value estimate is HK$0.3900 — implying the stock looks roughly 70.9% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 0314 generated revenue of HK$2.1B at a net margin of -6.0%. Revenue declined 61.5% year over year. It earns a return on equity of -12.1%. The balance sheet holds a net cash position of HK$284M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$2.1B

Revenue growth (YoY) -61.5%

Net margin -6.0%

Return on equity -12.1%

Free cash flow HK$127K FY2025

Operating margin -3.8%

More key figures

EPS (TTM) HK$-0.1200

Net cash HK$284M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0314 reported revenue of HK$2.0B in FY2025 versus HK$3.5B in FY2021, a compound −12.7%/yr. Reported net income was −HK$121M in FY2025.

Revenue −12.7%/yr

FY21 HK$3.5B

FY22 HK$4.1B

FY23 HK$4.7B

FY24 HK$4.6B

FY25 HK$2.0B

Net income

FY21 −HK$3.7B

FY22 −HK$1.4B

FY23 −HK$256M

FY24 −HK$324M

FY25 −HK$121M

Is 0314 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$999.49	R$1,236	+24%
Cencora, Inc C1CO34	R$707.04	R$79.88	-89%
Cardinal Health, Inc CAH	$201.74	$92.07	-54%
Sigma Healthcare Limited SIGGF	$2.35	$0.6300	-73%
Sitka Gold Corp SIG	A$2.92	A$1.20	-59%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥45.15	+183%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0314 (0314) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$0.3900 versus a price of HK$1.34 — about −71% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0314?

Our model-based fair value for 0314 is HK$0.3900 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$1.34.

What is the quality score of 0314?

0314 has a Quality Score of 46/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0314 (0314)?

0314 reported trailing-twelve-month revenue of about HK$2.1B (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0314?

The net profit margin of 0314 is about -6.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.